Aflac on Pace for Largest Percent Decrease Since May 2025 -- Data Talk
Dow Jones2026/08/19 16:05Aflac Incorporated (AFL) is currently at $116.70, down $5.03 or 4.13%
--Would be lowest close since June 22, 2026, when it closed at $116.55
--On pace for largest percent decrease since May 1, 2025, when it fell 4.75%
--Currently down two of the past three days
--Down 8.46% month-to-date
--Up 5.83% year-to-date
--Down 9.92% from its all-time closing high of $129.55 on July 28, 2026
--Up 8.16% from 52 weeks ago (Aug. 20, 2025), when it closed at $107.90
--Down 9.92% from its 52-week closing high of $129.55 on July 28, 2026
--Up 10.49% from its 52-week closing low of $105.62 on Sept. 2, 2025
--Traded as low as $116.62; lowest intraday level since June 23, 2026, when it hit $116.57
--Down 4.2% at today's intraday low; largest intraday percent decrease since April 30, 2026, when it fell as much as 5.73%
--10th worst performer in the S&P 500 today
All data as of 12:03:45 PM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
August 19, 2026 12:05 ET (16:05 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BNP Paribas gives Microsoft (MSFT.US) a "Buy" rating: Azure price increases will be gradually implemented after contract renewals, and a deal with SpaceX may be announced soon.
BNP Paribas has rated Microsoft as "Buy" with a target price of $549.
Iranian President will head to New York for UN meeting
"Big Short" Burry opens a position in QXO (QXO.US), betting on building products integration and undervaluation; stock price rises over 7%
Investor Michael Burry disclosed that he has purchased common and preferred shares of QXO (QXO.US), a building products company, citing its integration strategy and the currently depressed stock price. The stock surged 7.2% on Monday.
700,000 new elderly patients join, Eli Lilly (LLY.US) dominates 70%: The first Medicare weight loss drug coverage report released
Dave Ricks, CEO of Eli Lilly (LLY.US), said in an interview on Monday that since Medicare began coverage for obesity drugs in July, 700,000 new elderly patients have started using GLP-1 medications.